利培酮对首发精神分裂症S100B蛋白含量影响与疗效关系

目的: 探讨首发精神分裂症S100B蛋白是否异常;利培酮对S100B影响与疗效之间关系。方法: 收集符合美国精神障碍诊断与统计手册第4版诊断标准首发精神分裂症住院患者53例,正常对照58例。患者组单一利培酮治疗12周,阳性和阴性综合症量表(positive and negative syndrome scale, PANSS)、临床总体印象量表(clinical general impression, CGI)、汉密尔顿抑郁量表(hamiton depression rating scale, HAMD)评定病情,酶联免疫吸附法(enzyme linked immunosorbent assay, ELISA)检测研究对象的S100B含量。结果: 基线患者组的S100B蛋白含量显著高于正常对照组(P<0.01)。12周利培酮治疗后S100B含量显著低于治疗前,但仍高于正常对照(P<0.05)。基线S100B蛋白含量与发病年龄、HAMD评分呈显著负相关(r=-0.22, -0.23, P均<0.05);治疗后S100B蛋白含量有效组低于无效组,与治疗前后PANSS减分值、阴性症状减分值呈显著负相关(r=-0.28、-0.31, P均<0.05)。结论: 首发精神分裂症S100B含量显著高于正常对照;利培酮治疗降低S100B含量且与临床疗效有一定的相关性;精神分裂症患者中枢神经系统可能存在着结构性损伤。

Effect of risperidone on S100B levels and relationship with treatment response in first-episode schizophrenic patients

AIM: To study if S100B levels is abnormity, to study the effect of risperidone on S100B levels and relationship between S100B levels and treatment response in first-episode schizophrenic patients. METHODS: Fifty-three first-episode schizophrenia inpatients according to DSM-IV were treated only with risperidone for 12 weeks, the Positive and Negative Syndrome Scale (PANSS), Clinical General Impression (CGI) and Hamiton Depression Rating Scale (HAMD) were estimated at the baseline and the endpoint to evaluate the clinical efficacy. The serum S100B levels of the patients at the baseline and the endpoint and the 58 healthy controls were assayed using Enzyme Linked Immunosorbent Assay (ELISA). RESULTS: The serum S100B levels of the patients groups were significantly higher than the controls (P<0.01) at the baseline, were significantly decreased after 12 weeks treatment with risperidone but remained significantly higher than controls (P<0.05). The serum S100B levels was negative correlated with the age of onset and score of HAMD(r= -0.28, -0.31, P all <0.05)at baseline, The serum S100B levels were significantly lower in the treatment responders comparing no-responders, were negative correlated with reduction of PANSS total score and negative subscore from baseline to 12 weeks (r=-0.28, -0.31, P all <0.05). CONCLUSION: The serum S100B levels of the schizophrenic patients are significantly higher than the healthy controls, Risperidone treatment reduced the S-100B levels that were associated with treatment response, indicating that patients with schizophrenia may suffer structural damage in central nervous system.